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INTRODUCTION
Labour  is  a  natural  physiological  phenomenon  of  child  birth.   It  is  a 
multifactorial  spontaneous  process  which  involves  myometrial  contractions, 
cervical  ripening  and dilatation,  and expulsion of  the  fetus  and placenta  in  an 
orderly manner.  In the process of labour, polarity of the uterus is maintained by 
active  contraction  of  upper  uterine  segment.   The  driving  forces  of  uterine 
contraction act upon the cervix which plays the role of innocent obstruction due to 
passive tissue resistance.  It has been proved that cervical dilatation is one of the 
important factors which determine the duration of labour
Sometimes it is observed that although uterine contractions are good, the 
cervix fails to dilate or dilates very slowly or partially.  The most common cause 
of prolonged first stage of labour is cervical spasm due to the overactivity of the 
circular  muscle  fibres  of  cervix,  which  may  be  increased  in  presence  of 
inflammation injury or fibrosis of cervix or due to fear tension pain syndrome. 
Prolonged labour results in maternal exhaustion.  At this crucial juncture, some 
medication which overcomes the functional overactivity of the circular muscles of 
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cervix,  without  giving  rise  to  complications  would  help  the  patient  and  the 
obstetrician.
Active management of labour was introduced into clinical practice in 1963 
at National Maternity Hospital, Dublin.  It’s aim was to reduce maternal and fetal 
distress,  shorten  the  duration  of  labour  and  anticipation  and  management  of 
complications. Cervical smooth muscle relaxants are well accepted addendum to 
the principle of active management of labour.   The present study was done to 
compare the efficacy of Drotaverine hydrochloride and Valethamate bromide on 
cervical dilatation in active labour in relation to a control group.  
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AIM OF STUDY
The study is a prospective study design which aims
1. To find out the average duration of Active phase of labour in normal term 
parturient in primigravidae and multi gravidae.
2. To  compare  the  effects  of  drugs  Drotaverine  Hydrochloride  and 
Valethamate Bromide in 
a. Shortening the duration of active phase of labour
b. Side effects on mother and fetus if any.
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REVIEW OF LITERATURE
HISTORICAL ASPECTS :
Valethamate  bromide  was  described  by  Steinmann  in 1953.   It  causes 
reduction  in  duration  of  labour  by  18-30  %  as  described  by  Beck  in 1956, 
Schildbach 1954 and Kishore N and Agarwal 1962.
It normalizes the irregular uterine contractions and improves the process of 
cervical dilatation as described by Walter 1957.
Prof. Anjaneyulu et al 1973  observed the shortening of Ist stage due to 
faster cervical dilatation compared to control group by 35 % but did not observe 
any effect on second or third stage of labour
Bhau et al 1979 claimed that average time taken for full cervical dilatation 
becomes shorter after injection of Valethamate bromide, irrespective of the initial 
cervical dilatation and parity of the patient.
Shrivastava et al 1979 did not find any change in the basal tone and in the 
intensity of uterine contractions by tachometric assessment.  The same team found 
45 % reduction in first stage of labour in primi and 46 % in multi and no change in 
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second stage of labour.
Prof. Bhattacharjee et al in 1983-84 observed 89 % cases of spontaneous 
vaginal deliveries 4 % cases of abdominal deliveries and 5 % forceps deliveries 
with Valethamate.
A. E. Czeizel  and M. Rocker Baurer (1989-90) studied about Drotaverine 
hydrochloride  in  detail,  and  its  teratogenic  effect  on  the  fetus  as  this  was 
developed mainly for threatened abortion initially.
Shepard TH – John Hopkins University (1992)  also studies the effect of 
this drug in hastening cervical dilatation and found favorable results.
Dr. Jones Demeter (1996) did extensive analysis of this drug in first stage 
of labour and found 50 – 60% reduction in the duration of labour.
Goswami  B,  Sarkar  M,  and  Biswas  B, who  presented  the  efficacy  of 
Drotaverine  in  the  active  management  of  labour,  at  the  XVI  FIGO  World 
Congress  of  Gynecology  and  Obstetrics  at  Washington,  September  2000, 
concluded that Drotaverine shortens the first stage by 2.8 hours as compared to a 
control group, and also hastens cervical dilatations by 1.3 to 2.04 cm per hour as 
compared to a control group.
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A meta-analysis of 14 prospective, randomized controlled clinical studies 
that  compared  Drotaverine  with  placebo  and/or  Valethamate,  presented  at  the 
XVII  FIGO  World  Congress  in  2003,  concluded  that  the  decrease  in  mean 
duration of first stage of labour with Drotaverine is 109 minutes compared with 
placebo, and 37.62 minutes compared with Valethamate. The difference in mean 
rate of cervical dilatation with Drotaverine showed that, compared to Valethamate 
and placebo, Drotaverine achieved faster rates of cervical dilatation, which was 
statistically significant.
THE CERVIX IN PREGNANCY AND LABOUR
The cervix  is  a  thick walled,  cylindrical  connective  tissue structure  that 
tapers at its inferior extremity, which is relatively inert and firm during most of 
pregnancy, and becomes soft and ripe as time for parturition approaches.  During 
parturition, it loses its elasticity, plasticity and viscosity resulting in full cervical 
diltation  (STYS 1986).   Some of  the  these  changes  are  evident  quite  early  in 
pregnancy (Anthony et al 1982)
There are 3 main structural components of the cervix,
- Smooth muscle
- Collagen
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- Connective tissue ground substance containing glycosaminoglycans.
According  to  Rorie  and  Newton,  the  muscle  contents  as  determined  by 
planometry is
Corpus – 69 %
Cervix Upper 1/3 – 29 %
Middle 1/3 – 18 %
Lower 1/3 – 6 %
Collagen dominates the cervical stroma.  Collagen types I and III are the 
main types found in the human cervix.  Kleissl et al found 62-80 % type I collagen 
and 20-38 % type III collagen.  The glycosaminoglycans constitute about 1 % of 
dry tissue, dermatan sulphate being the most common (52-73%). Hyaluronic acid 
8-22 % and heparin sulphate 6-13 % being found in smaller amounts
Changes that take place in collagen and the connective tissue matrix are the 
primary  factors  in  cervical  ripening.  These  features  are  incorporated  into  the 
scoring system described by Bishop as an index of the proximity of spontaneous 
labour,  and  included  cervical  position,  consistency,  dilatation,  and  length  or 
effacement.  During cervical ripening 2 complementary changes take place.
1. Collagen breakdown and rearrangement  of  the  collagen fibres  (Harness 
and Harness 1959, Dan Forth et al)
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2. Alterations in the relative amounts of the various glycosaminoglycans – 
There is a striking increase of hyaluronic acid with a concomitant decrease 
in  dermatan  sulphate.  Hyaluronic  acid  itself  has  a  high  water  binding 
capacity.
The  collagen  fibres  loosen  when  the  mucopolysaccharide  substance 
between  them  becomes  hydrated  and  the  whole  cervix  is  softened. 
Hydroxyproline  is  an  indicator  of  the  amount  of  collagen,  and  Uldjerg  et  al,  
showed that  low concentrations  of  cervical  hydroxyproline  are  associated with 
faster  rates  of  cervical  dilatation.  These  changes  usually  take  place  late  in 
pregnancy and are influenced by various hormones esp. estrogen.
It  is  widely  accepted  that  prostaglandins  have  discrete  softening  and 
effacement effects on cervix even without uterine contractions (Hiller and Wallis  
1981  –  Gao  schen et  al  1985).  Cervical  tissues  have  the  ability  to  generate 
prostaglandins (Ellwood et al 1980)  The administration of progesterone receptor 
antagonist RU486 for induction of abortion was associated with cervical ripening 
(Wolf et al 1989 Elger et al 1990, Silvestre et al 1990) Human cervical tissues 
possess  estrogen  receptors  (Honnelier  et  al  1989)  and  estrogen  including 
dehydroepiandrosterone sulphate have shown to be accumulated in ripening cervix 
(Ishikawa  and  Shimizu,  1989)  Relaxin,  an  ovarian  polypeptide  hormone, 
increases  significantly  in  cervix  towards  end of  pregnancy  (Von Maillot  et  al  
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1979).
Prolonged  labour  is  a  problem  especially  prolonged  I  stage  when 
incomplete cervical dilatation appears to be the only cause holding back descent of 
the presenting part.  This led to an increased use of anti spasmodies for the past 
15-20  years.  Drugs  containing  belladonna  alkaloids  are  often  used  for  this 
purpose, but they have considerable adverse effects.
Hans Ulrich Beck 1956 first reported about the use fullness of Valethamate 
bromide in accelerating cervical dilatation and shortening the duration of labour 
by 18-30 % and normalization of irregular uterine contraction.
AE  Czeizel  and  M.  Rockenbauer  (1980-81) first  reported  about  the 
usefulness of Drotaverine Hydrochloride in threatened abortion and later, on its 
usefulness in accelerating cervical dilatation in labour.
Indeed, pharmacological manipulation of the cervix to produce dilatation 
without inducing myometrical activity would be similar to surgically removing the 
resistance of the cervix.
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PATTERNS OF LABOUR
Labour is divided into 3 stages.
First stage :  From the onset of true labour pains to complete dilatation of the 
cervix (10 cm)
Second  stage :  Begins  with  complete  dilatation  of  the  cervix  and  ends  with 
delivery of the infant.
Third stage : Denotes time interval from delivery  of the infant to delivery of the 
placenta.
Ist stage has 2 phases.
1. Latent phase
2. Active phase
Latent phase : commences with maternal perceptions of regular contractions and 
ends at between 3 and 4 cm of dilatation 
a. Cervix shortens from 3 cm to 0.5 cm length (effacement)
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b. Cervix dilates to 3-4 cm
Duration :
Primigravida – 20 hrs (95th percentile – statistical maximum)
Multigravida 14 hrs   
Factors that affect duration of latent phase :
- Excessive sedation or conduction analgesia 
- Poor cervical condition (eg. Thick, uneffaced, undilated) 
- False labour.
Active phase : Cervical dilatation of 3-4 cm or more, in the presence of uterine 
contractions  reliably  represent  the  threshold  for  active  labour.   It  has  3 
components.
a. Acceleration phase : Cervical dilatation 3-4 cm
b. Phase of maximum slope : cervical dilatation 4-9 cm 
c. Deceleration phase : cervical dilatation 9-10 cm
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Rate of cervical dilatation
Nullpiara – 1.2 cm / hr.    (minimum normal)
Multipara – 1.5 cm / hr.
Mean duration
Nullipara – 4.9 hrs.
Descent begins in the later stage of active dilatation, commencing at about 
7.8 cm in nullipara and becoming most rapid after 8 cm.
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Slope of descent of presenting part :
Greater than 1 cm / 1 hr – nullipara
Greater than 2 cms/ hr – multipara 
Deceleration phase duration should not exceed
Nullipara – 3 hours
Multipara – 1hour.
The characters of the active phase are usually predictive of the outcome of a 
particular labour.  Friedman considers the maximum slope as a good measure of 
the overall efficiency of uterine contractions, whereas, the deceleration phase is 
more reflective of fetopelvic relationships.
Friedman developed the concept of three functional divisions of labour.
a) Preparatory division 
- Little cervical dilatation
- Considerable changes in the connective tissue components of cervix
- Sensitive to sedation and conduction analgesia.
18
b) Dilatational division 
- Dilatation at its most rapid rate
- Unaffected by sedation or conduction analgesia
c) Pelvic division 
- Commences with deceleration phase of cervical dilatation.
- Cardinal fetal movements in mechanism of labour take place
ABBORMALITIES OF LABOUR
LABOUR PATTERNS
Diagnostic criteria
Nullipara Multipara
PROLONGATION DISORDER
Prolonged latent phase > 20 hr > 14 hr
PROTRACTION DISORDER
Protracted active phase dilatation <1.2 cm / hr  < 1.5 cm / hr.
Protracted descent <1 cm / hr  <2 cm / hr  
ARREST DISORDERS
Prolonged Deceleration phase > 3 hr > 1 hr
Secondary arrest of dilatation > 2 hr > 2 hr
Arrest of descent > 1 hr > 1 hr
Failure of descent – No descent in deceleration phase or second stage.
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Causes of labour abnormalities : As per ACOG (1995) abnormalities of labour 
are classified into 3 categories.
1. Abnormalities of the powers
• Hypotonic dysfunction
• Hypertonic dysfunction
• Poor maternal expulsive efforts
2. Abnormalities of the passenger (fetus) 
• Excessive fetal size.
• Malpresentation
• Malposition
• Abnormal attitude
• Congenital abnormalities
3. Abnormalities of the passage (pelvis)
• Cephalopelvic disproportion.
o Absolute
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o Relative
Labour Abnormalities due to cervical causes :
Rigidity of cervix – Hypertrophic rigidity
Cicatricial rigidity
Functional or spasmodic rigidity
Atresia of cervix
Sacculation of cervix
Tumours of cervix
Hypertrophic rigidity :
Causes : Prolapse uterus
Chronic cervictis
Cicatricial rigidity :
Causes : After amputation of cervix
Conisation
Curettage
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Long standing prolapse
Atresia of cervix : (reported by Morgan and Price and Slugett H)
Causes: Mucosal agglutination due to inflammation.
Ring Biopsy
Sacculation of wall of cervix : very rare
Ballooning out of one or other walls of cervix.  The internal os is found 
tucked away up behind or in front of the presenting part.
Conglutination of the external os presenting as pin hole os.
Tumours of cervix : 
• Fibromyoma.
• Carcinoma.
Treatment :
Epidural  analgesia  was  advocated  early  by  Arthur and Johnson,  who 
showed that this not only gave time for cervix to dilate, but also that the nerve 
blocking had a specific effect.  But  Stud et al showed clearly that epidural 
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block  does  not  influence  rate  of  cervical  dilatation,  but  the  most  essential 
remedy  is  to  ensure  adequate  uterine  contractions.  Other  methods  of 
overcoming cervical resistance are
1. Vacuum may be applied and uterine forces supplemented by traction during 
contraction.
2. Duhrssen’s incisions of the cervix - pre requisite is cervix should be thin 
and well applied (Cope et al)
3. Accouchement force  – manual dilatation and pushing up the  lips  of  the 
cervix over the presenting part during contraction.
4. Caesarian section.
The physical state of the cervix determines the rate of cervical dilatation, 
and in addition modulates uterine wall  tension and intra uterine pressure.  This 
effect has been termed the cervical attenuation / augmentation of pressure or CAP 
effect.  Therefore a complaint cervix will result in rapid progress in labour, but 
owing to the compliance of the cervix and lower uterine segment, the wall tension 
is  reduced  and  the  pressure  attenuated.  Conversely,  a  non  compliant  cervix 
predisposes to slow labour progress and myometrial  activity directly translated 
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into uterine wall tension and high intra uterine pressures.
Full cervical dilatation is one of the important factors for any successful 
delivery.  Cervical spasm may set in either gradually or instantly during the Ist 
stage of labour, and it may be primary or secondary to any definite etiology. The 
relaxation of cervical muscle is believed to be an involuntary reflex action coupled 
with  rhythmic  contractions  of  the  body  of  the  uterus.  The  relaxation  is  also 
dependent  on  the  presenting  part  and  the  bag  of  membranes  which  act  as  a 
mechanical wedge.  A ball valve action of the presenting part especially the vertex 
is also helpful in dilatation.
Psychological  makeup  of  the  patient  and  apprehension  may  complicate 
cervical spasm.  Since the cause of cervical spasm is not fully known, it is difficult 
to treat the spasm with any specific drugs, but broadly the spasm may be due to
- Nervous mechanism
- Hormonal mechanism
- Both
Any drug to relieve the spasm has to act through these mechanisms or act 
on the smooth muscles directly.
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PHARMACOLOGIC REVIEW OF VALETHAMATE BROMIDE AND 
DROTAVERINE HYDROCHLORIDE
VALETHAMATE BROMIDE
It is an ester with a quaternary ammonium compound.  The unique feature 
of this drug is that it blends the antichololinergic properties of atropine and the 
musculotropic action of papaverine at the same time.  It acts by blocking
1. Cholinergic receptors
2. Ganglia
3. Direct musculotropic action
4. Spasmolytic action
Like atropine it inhibits the conduction of stimuli from the parasympathetic 
systems  to  the  organs  of  response.  It  differs  from atropine  by  its  more  rapid 
detoxification  and  lesser  effect  on  other  functions  of  parasympathetic  system. 
Valethamate  bromide  relieves  cervical  spasm  due  to  para  sympathetic  over 
excitement, has a good effect on smooth muscles of uterus and helps in cervical 
dilatation.  Its action is selective and that is the reason it does not exhibit the usual 
side effects of anticholinergic drugs. It does not affect respiratory or circulatory 
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functions.
Side effects : Drying of all secretins
Flushing of face
Tachycardia
Blurring of vision
Difficulty in swallowing
Constipation / Urinary retention
Glaucoma
Rarely arrhythmias
Contra indications: Glaucoma
Pyloric stenosis  
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Ulcerative colitis
Paralytic ileus.
Drug interactions: Potentiated by other antispasmodics.
Preparation : Injection – 8 mg in 1 ml
Tablet – 10 mg
Dosage – 8 mg IM / IV once every hour.
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DROTAVERINE HYDROCHLORIDE
Leroy et al 1990 found that type IV phosphodiesterase enzyme is present in 
increased  concentration  in  myometrium  at  term  suggesting  its  contribution  in 
regulation of uterine motility.
Drotaverine, a benzyl isoquinoline derivative and a phosphodiesterase type 
IV inhibitor, causes smooth muscle relaxation by increasing the intracellular levels 
of cyclic adenosine monophosphate (CAMP) secondary to inhibition of phosphate 
diesterase.   Drotaverine  produces  facilitated  relaxation  of  smooth  muscle  cells 
with high concentration of phosphodiesterase IV in the bile duct, ureter and uterus. 
The pharmacological doses of drotaverine relaxes only the smooth muscle cone of 
the lower uterine segment and cervix where the concentration of PDE IV per gram 
of  tissue  is  relatively  less.   Hence  active  labour  pains  are  not  inhibited  by 
Drotaverine.
Its  action  does  not  involve  the  autonomic  nervous  system and  so  side 
effects  are  minimal.  The  drug  is  generally  well  tolerated  with  a  good  safety 
profile.
Absorption, fate and excretion.
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Absorbed from GIT
Parentral absorption rapid
T ½ - 1 hour 15 minutes.  Excreted by kidney.
Side Effects
Too rapid intravenous injection should be avoided to prevent drop in arterial 
blood  pressure.   In  rare  cases,  nausea  and  vertigo  may  occur  after  rapid  IV 
injection.   A  case  control  study  at  the  Department  of  human  genetics  and 
teratology, National Institute of Public Health (1980-1991) reported that the use of 
Drotaverine was not associated with any teratogenic effect.
Drug interactions : Levodopa (Antiparkinsonian effect may decrease)
Concurrent use of analgesics, antimuscarinics, or benzodiazepines have additive 
beneficial effect with drotaverine.
Indications : Spastic conditions of gastrointestinal tract, biliary tract, uterus and 
urogenital tract, renal colic and irritable bowel disease.
Dosage : Tablet – 80 mgm adults – 4th houly
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Injection – 40 mgm 2nd hourly
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MATERIALS AND METHODS
This prospective study was conducted in Govt. Hospital for Women and 
children  at  the  Institute  of  Obstetrics  and  Gynaecology  attached  to  Madras 
Medical College from February 2004 to January 2006.
SELECTION CRITERIA :
INCLUSION CRITERIA :
1. Term pregnancy in active labour – initial cervical dilation of 3 – 4 cms and 
cervical effacement 75%.
2. Vertex presentation
3. No cephalopelvic disproportion
4. No high risk factors
5. Labour was accelerated with syntocinon whenever needed.
6. All the patients were managed actively
The patients were divided into 3 groups of 100 patients
Group I - Control Group – Normal labour patients – 100 Nos.
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Group II - Patients who received Inj. Drotaverine Hydrochloride – 100 Nos
Group III - Patients who received Inj. Valethamate Bromide – 100 Nos.
Primigravidae  and  multigravidae  who  fulfilled  the  above  criteria  were 
assigned Group I, Group II, Group III as they arrived, after obtaining an informed 
consent.
EXCLUSION CRITERIA
1. Medical disorders complicating pregnancy
2. Obstetric complications within high risk category
3. Malpresentation
4. Women with previous caesarian section
History
A detailed history regarding age, parity, socioeconomic status, occupation, 
booking,  gestational  age,  H/o.  any  medical  disorders  or  high  risk  factors  was 
elicited.
CLINICAL EXAMINATION:
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A thorough general examination was done followed by detailed obstetric 
examination to know the height of fundus, presentation and position of the fetus, 
fetal heart sounds with respect to rhythm, rate and intensity.
Vaginal examination was done in detail to know the position, effacement 
and dilation of cervix, position and station of presenting part, presence or absence 
of membranes, and for assessment of pelvis and cephalopelvic disproportion.
MANAGEMENT
All these patients were entered into partograms and the progress of labour, 
uterine contractions and the fetal heart rate were monitored carefully.
Patients were selected randomly and were allotted to 1 of following groups, 
regardless of age and parity.
Group I - Control Group
Group II - Received  1  ampoule  of  Drotaverine  Hydrochloride  40  mg 
intravenously at 2 hourly intervals up to a maximum of 3 doses, 
starting at 3-4 cms cervical dilatation.
Group III - Received, 1 ampoule of Valethamate bromide 8mg intravenously at 
hourly intervals up to a maximum of 3 doses, starting at 3-4 cms 
cervical dilatation.
Per vaginal examination was carried out usually at an interval of  2 hours 
and  findings  noted.  Artificial  rupture  of  membranes  was  done  soon  after 
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administration of drug at 4 cm cervical dilatation, and duration of active phase of 
first and second stages of labour recorded. Standard parameters for maternal and 
fetal  well  being  were  monitored  as  specified  by  Dawn.  If  desired  rate  of 
contractions  were  not  achieved  oxytocin  drip  was  started.  Mode  of  delivery, 
maternal side effects and fetal outcomes were noted and tabulated. Appropriate 
non-parametric tests, X2 test and analysis of variants (ANOVA) were applied for 
assessment of statistical significance.     
OBSERVATIONS
Table – I
DISTRIBUTION OF CASES ACCORDING TO AGE GROUP
Age in years Group IN = 100
Group II
N = 100
Group III
N = 100 Percentage
15 – 20 24 31 22 25.9%
21 – 25 49 56 57 54%
26-30 23 13 19 18.3%
31 – 35 4 - 2 2%
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X2 = 8.21 P = 0.16 (Not significant) 
Patients in age group of 21 – 30 years contributed to 72.3%. 
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TABLE 2
DISTRIBUTION OF CASES ACCORDING TO GRAVIDITY 
Parity Group IN = 100
Group II
N = 100
Group III
N = 100 Percentage
Primi 50 50 50 50%
Gravida 2 31 38 34 34.3%
Gravida 3 16 8 12 12%
Gravida 4& 5 3 4 4 3.67%
X2 = 3.57 P = 0.74 (Not significant)
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TABLE 3A
DURATION OF ACTIVE PHASE OF LABOUR IN DIFFERENT 
GROUPS IN PRIMIGRAVIDAE
Group No.of Cases
Mean 
Duration 
(minutes)
Difference of 
means 
(minutes
Difference in 
percentage
I 50 203.4
II 50 94.6 108.8 53%
III 50 118.6 84.8 41%
Drotaverine Hydrochloride shortened the mean duration of active phase of 
labour  in  primigravidae  by  108.8  minutes  (53%  reduction)  and  Valethamate 
Bromide by 84.8 minutes (41% reduction) compared to control group. 
F = 312.64,   (P =  0.001) – Statistically Significant.
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TABLE 3B
DURATION OF ACTIVE PHASE OF LABOUR IN DIFFERENT GROUPS 
IN MULTIGRAVIDAE
Group No.of Cases
Mean 
Duration 
(minutes)
Difference of 
means 
(minutes
Difference in 
percentage
I 50 163.76
II 50 78.94 84.82 57%
III 50 104.10 59.66 36%
Drotaverine hydrochloride shortened the duration of active phase of labour 
in multigravidae by 84.82 minutes. (57% reduction) and Valethamate Bromide by 
59.66 minutes. (36% reduction) compared to control.
F = 159.35,  P = 0.001 – Statistically Significant.
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TABLE 4A
RATE OF CERVICAL DILATATION IN ACTIVE PHASE IN 
PRIMIGRAVIDAE
Group No.of Cases Average rate of cervical dilatation (cm /hr)
Difference of 
Means 
(cm /hr)
I 50 2.09
II 50 4.59 2.5
III 50 3.64 1.55
Drotaverine hydrochloride increased the average rate of cervical dilatation 
by 2.5 cm/hr in primigravidae, and Valethamate bromide by 1.55 cm/hr compared 
to control group.  
 F = 196.26, P =  0.001 – Statistically Significant.
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TABLE 4B
RATE OF CERVICAL DILATATION IN ACTIVE PHASE IN 
MULTIGRAVIDAE
Group No.of Cases Average rate of cervical dilatation (cm /hr)
Difference of 
Means 
(cm /hr)
I 50 2.65
II 50 5.58 2.93
III 50 4.2 1.55
Drotaverine Hydrochloride increased the average rate of cervical dilatation 
by  2.93  cm/hr  in  multigravidae  and  Valethamate  bromide  by  1.55  cm/hour 
compared to control group.
F = 118.67 P = 0.001 – Statistically Significant.
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TABLE 5A
DURATION OF II STAGE OF LABOUR IN PRIMIGRAVIDAE
Group No. of cases Mean Duration 
(minutes)
Difference of means 
(minutes)
I 50 22.30
II 50 19.62 2.68
III 50 21.08 1.22
There  was  no  significant  shortening  of  II  stage  of  labour  with  either 
Drotaverine  Hydrochloride  or  Valethamate  Bromide  in  primigravidae  in  all  3 
groups. 
F = 1.23,   P = 0.15, Not significant.
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TABLE 5B
DURATION OF II STAGE OF LABOUR IN MULTIGRAVIDAE
Group No. of Cases
Mean Duration 
(minutes)
Difference of Means
(minutes)
I 50 20.68
II 50 18.86 1.82
III 50 19.82 0.86
The duration of second stage of labour is not significantly different in the 3 
groups in multigravidae also.
F = 1.53,  P = 0.23, Not significant.
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TABLE 6A
ACTIVE PHASE / FIRST INJECTION DELIVERY INTERVAL IN 
PRIMIGRAVIDAE:
Groups Gravidity
Active Phase 
First Injection – 
Delivery Interval 
(minutes)
Difference of 
Means 
(minutes)
Difference in 
Percentage
Group I Primigravidae 225.7
Group II Primigravidae 114.62 111.08 49%
Group III Primigravidae 139.78 85.92 38%
The mean first  injection delivery  interval  was  shortened by  Drotaverine 
Hydrochloride  in  primigravidae  by  111.08  mts  (49%  reduction)  and  with 
Valethamate Bromide by 85.92 mts (38% reduction) compared to active phase – 
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delivery interval in control group.
P = 0.001, Statistically Significant.
TABLE 6B
ACTIVE PHASE / FIRST INJECTION DELIVERY INTERVAL IN 
MULTIGRAVIDAE :
Groups Gravidity
Active Phase 
First Injection – 
Delivery Interval 
(minutes)
Difference of 
Means 
(minutes)
Difference in 
Percentage
Group I Multigravidae 184.44
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Group II Multigravidae 98.6 85.84 96.5%
Group III Multigravidae 123.52 60.92 33%
The  first  injection  delivery  interval  was  shortened  by  Drotaverine  in 
mutigravidae by 85.84 minutes (46.5% reduction) and with Valethamate by 60.92 
minutes (33% reduction)  compared to  active  phase  delivery  interval  in  control 
group.
P = 0.001, Statistically Significant
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TABLE 7
OXYTOCIN AUGMENTATION
Oxytocin Group 1
n = 100
Group II
n = 100
Group III
n = 100
Used 52% 46% 48%
Not used 48% 54% 52%
52%, 46% and 48% required oxytocin augmentation in groups I, II and III 
respectively.  Hence  both Drotaverine  Hydrochloride  and Valethamate  Bromide 
had no effect on uterine contractions.
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TABLE  8  
C
HARACTER OF AMNIOTIC FLUID
Type of liquor Group I Group II Group III Fetal outcome
Clear 89 93 90 Good
Thin meconium 7 5 7 Good
Thick Meconium 4 2 3 Good
Patients with thin meconium stained liquor in all three groups were NST 
Reactive, delivered vaginally and had Apgar > 7/10 at 5 minutes.
All cases of thick meconium were NST Reactive. In control group, 2 were 
taken up for LSCS, 1 delivered by outlet forceps and 1 delivered vaginally, all had 
Apgar > 7/10 at 5 minutes.
In Drotaverine group both delivered vaginally – one as face to pubis. Both 
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were vigorous babies and had Apgar > 7/10 at 5 minutes.
In Valethamate group 1 was delivered by LSCS and 2 by outlet forceps. All 
had Apgar > 7/10 at 5 minutes.
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TABLE  9A  
MODE OF DELIVERY IN PRIMIGRAVIDAE
Group No. of Cases
Normal vaginal 
Delivery
Forceps 
Delivery LSCS
I 50 46 2 2
II 50 49 1
III 50 48 1 1
There was no increase in instrumental delivery in either of the groups given 
Drotaverine or Valethamate in Primigravidae.  Indications for LSCS in control 
group were fetal distress and secondary arrest of cervical dilation. Indications for 
LSCS in drug groups was not pertaining to drug administration.
X2 = 6.18 P = 0.19 Not Significant 
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TABLE 9  B  
MODE OF DELIVERY IN MULTIGRAVIDAE
Group No. of Cases
Normal vaginal 
Delivery
Forceps 
Delivery LSCS
I 50 47 2 1
II 50 49 1 -
III 50 49 1 -
There was no increase in instrumental delivery in either of the groups given 
Drotaverine or Valethamate in multigravidae. Indication for LSCS in group I was 
fetal distress. Indications  for  outlet  forceps  in  all  groups  were  failure  of 
secondary powers.
X2  =  6.12   P = 3.19  Not significant 
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TABLE 10
RELATIONSHIP BETWEEN DRUGS AND FETAL OUTCOME
Group No. of Cases
APGAR SCORE
1 minute 5 minutes
< 7/10 > 7 / 10 < 7 /10 > 7 / 10
I
Primis – 50 2 48 - 50
Multis – 50 2 48 - 50
II
Primis – 50 1 49 - 50
Multis – 50 2 48 - 50
III
Primis – 50 3 47 - 50
Multis – 50 - 50 - 50
 
3% of newborns in all the 3 groups had Apgar score of < 7 at birth (1mt) 
and 1 newborn in control group required observation in NICU for 2 hours. All the 
newborns in all the 3 groups had Apgar score of > 7 at 5 minutes. There was no 
intrapartum or early neonatal deaths in all the study groups.
X2 = 0.5 P = 0.568 Not significant 
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TABLE 11
THIRD STAGE COMPLICATIONS
Complications Drotaverine Group Valethamate Group Control
Cervical tears 2% 2% -
Atomic PPH - - -
Cervical tear was noted in 2% of cases in Group I and Group II. No case of 
postpartum hemorrhage was observed in any woman.
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TABLE 12
COMPARISON OF NUMBER OF INJECTIONS GIVEN IN THE 
DIFFERENT GROUPS
Group No. of Cases
No. of Injections
1 ≥  2
Group II 100
Primi (49)
Multi (44)
93%
Primi (1)
Multi (6)
7%
Group III 100
Primi (24)
Multi (37)
61%
Primi (26)
Multi (13)
39%
The number of injections required in both groups was limited to 3; single 
injection was required in 93% cases in Group II, while in Group III 61% cases 
required single injection and 39% cases required 2 or more injections.
X2 = 28.91 OR = 8.5 95% CI = 3 – 22
P = 0.001 Statistically significant  
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TABLE 13
UNTOWARD MATERNAL EFFECTS AFTER DROTAVERINE 
HYDROCHLORIDE AND VALETHAMATE BROMIDE
Side effects Group II Dose of Drug in mg Group III
Dose of Drug 
in mg
Dryness of mouth 1 80 4 16
Vomiting 1 80 1 24
Tachycardia 1 80 3 16
In Drotaverine group, 3% exhibited side effects while in the Valethamate 
group 8% exhibited side effects. Most common side effects in Valethamate group 
were dryness of mouth and tachycardia. In both groups side effects were noted 
after two or more injections hence they are dose related.
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 TABLE 14
TESTS OF STATISTICAL SIGNIFICANCE
Group 
I
Group 
II
Differenc
e of 
means 
(mts)
% Group III
Difference 
of means 
(mts)
%
Anova Test 
P value & 
significance
No.of 
Cases
100 100 100
Mean 
Duration 
of Active 
Phase 
(minutes)
183.58 
± 
72.28
86.77± 
39.82
96.81 52% 113.35
± 43.32
70.23 38% F = 34.77
P = 0.001 
Significant
Mean 
rate of 
cervical 
dilatation 
(cm/hr)
2.37 ± 
1.04
5.09 ± 
2.3
2.72 3.92 ± 
1.72
1.55 F = 236.44
P = 0.001 
Significant
Mean 
Active 
phase / 
Drug – 
Delivery 
Interval 
(minutes
205.07 
± 
75.66
106.61 
± 
43.96
98.46 48% 131.65 
± 45.1
73.42 36% F = 332.86
P = 0.001
Significant
Thus Drotaverine hydrochlomide and Valethamate bromide achieved 52% 
and  38%  reduction  in  mean  duration  of  active  phase  of  labour  respectively 
compared with control group. The mean rate of cervical dilatation was 2.72 cm/hr 
faster with Drotaverine and 1.55 cm/hr with epidosin compared to control. The 
mean  drug  delivery  interval  was  48%  shortened  by  Drotaverine  and  36% 
shortened by Valethamate compared to Active phase Delivery interval of Control 
group.
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TABLE 15 
COMPARISON OF MATERNAL AND FETAL OUTCOMES
Outcomes Group I Group II Group III
Mode Vaginal 93 98 97
Outlets Forceps 4 2 2
LSCS 3 - 1
Cervical tears - 2% 2%
Atonic PPH - - -
Meconium stained liquor 12% 7% 10%
Maternal Side Effects 4% 3% 8%
Apgar < 7/10 at 1 mt 3% 3% 3%
Apgar > 7 at 5 mt 100% 100% 100%
Drotaverine hydrochloride and Valethamate Bromide compared favourably 
with  each  other  with  respect  to  maternal  and  fetal  outcomes,  except  that 
Valethamate had a higher incidence of maternal side effect.
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DISCUSSION
Various perspective, randomized controlled clinical studies that compared 
Drotaverine hydrochloride with placebo, and / or Valethamate bromide have been 
carried  out.  In  the  present  study,  Drotaverine  hydrochloride  and  Valethamate 
bromide were given intravenously at  3-4cms cervical  dilatation in 2 groups of 
demographically  similar  women  with  term  pregnancy  in  active  labour,  and 
compared with a control group.
It  was noted that the mean duration of active phase of labour in control 
group was 183.58 ± 72.28 minutes, and 86.77 ± 39.82 minutes in Group II and 
111.35 ± 43.32 minutes in Group III, which is comparable to the study conducted 
by Devinder et al (2001)  (96.34 ± 59.45 minutes with Drotaverine and 128.78 ± 
58.99  minutes  with  Valethamate).  Randomised  controlled  clinical  studies 
presented  at  the  XVII  FIGO World  Congress  held  that  the  decrease  in  mean 
duration  of  Active  phase  with  Drotaverine  was  109 minutes  compared    with 
placebo, and 37.6 minutes compared with Valethamate. In the present study, the 
decrease is 96.81 minutes in Drotaverine group compared to control, and 24.58 
minutes compared with Valethamate.
The rate of cervical dilatation was 2.37 ± 1.04 cm/hr in Group I, 5.09 ± 
2.3cm/hr in Group II, and 3.92 ± 1.72 cm/hr in Group III respectively which is 
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comparable  to  the  study  by  Devinder  et  al  (2001) (4.99  ±  2.21  cm/hr  with 
Drotaverine  and 3.74  ±  1.72  cm/hr  with  Valethamate).  Goswami  et  al  (2000) 
noted that Drotaverine hastens cervical dilatation by 1.3 to 2.04 cm/hr compared to 
control.  In  the  present  study,  cervical  dilatation  was  2.72cm/hr  faster  with 
Drotaverine compared to control and 1.17 cm/hr faster with Valethamate.
Both Drotaverine hydrochloride and valethamate bromide had no effect on 
the uterine contractions. 
The  mean  first  injection  delivery  internal  with  Drotaverine  is  106.61  ± 
43.96 minutes and 131.65 ± 45.1 minutes with Valethamate which is comparable 
to the study by  Devinder et al   (129.82 ± 63.75 minutes with Drotaverine and 
151.53 ± 60.47 minutes with Valethamate).    
The  average  duration  of  II  stage  of  labour  was  not  affected  by 
administration of drugs compared to control group. 
93% cases in Drotaverine group required single injection, while 69% cases 
required single injection and 39% required 2 or more injections in Valethamate 
group. The incidence of side effects was 3% with Drotarverine compared to 8% 
with Valethamate. Cervical tears were noted in 2% in both drug groups. No case 
of atonic PPH was noted in all 3 groups. 
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Regarding mode of delivery, in control group, 4 cases were delivered by 
outlet forceps and 3 cases by LSCS. In Drotaverine group, 2 cases were delivered 
by outlet forceps, and in Valethamate group 2 were delivered by outlet forceps and 
1 by LSCS. Thus there was no increase in instrumental delivery in either of the 
drug groups.
Regarding fetal outcome, thin meconium stained liquor was noted in 8%, 
5% and 7% of cases in Group I, II and III respectively. All were NST reactive, 
delivered vaginally, and had Apgar > 7/10 at 5 minutes.  Thick meconium was 
noted in 4 cases in control group – 2 delivered by LSCS, 1 by outlet forceps and 1 
delivered vaginally. Thick meconium noted in 2 cases in Drotaverine group were 
delivered vaginally, and of the 3 cases of thick meconium in Valethamate group, 1 
was delivered by LSCS and 2 by outlet forceps. All cases of thick meconium in all 
3 groups were NST reactive and had Apgar > 7/10 at 5 minutes. There was no 
intrapartum or early neonatal deaths in all 3 groups.
  
   
 
60
SUMMARY
• This  study  was  conducted  to  compare  the  efficacy  of  Drotaverine 
Hydrochloride  and  Valethamate  Bromide  on  cervical  dilatation  in  active 
labour, and adverse effects on maternal and fetal outcome.
• A total number of 300 parturients were studied
Group I Control Group – Received no drugs
Group II Received  intravenous  Drotarverine  hydrochloride  at  3-4  cms 
cervical dilatation at 2 hourly intervals upto a maximum of 3 doses
Group III Received  intravenous  Valethamate  bromide  at  3-4  cms  cervical 
dilatation at hourly intervals upto a maximum of 3 doses
• Mean duration of active phase of labour in control  group was 183.58 ± 
72.28 minutes. The duration of active phase is reduced by 96.81 minutes 
(52%  reduction)  in  Drotaverine  group  which  is  statistically  significant 
(p  =  0.001)  compared  with  control  and  24.58  minutes  faster  than 
Valethamate.
• There was significant difference in rate of Cervical dilatation between the 
control and other 2 groups (p = 0.001) with Drotaverine achieving 2.72cm/
hr faster dilatation and Valethamate achieving 1.55cm/hr faster dilatation 
compared to control.
• Both  Drotaverine  Hydrochloride  and  Valethamate  had  no  effect  on  the 
uterine contractions.
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• The mean first  injections to Delivery interval  is significantly reduced in 
both  groups  given  drugs  48%  reductions  with  Drotaverine  and  36% 
reduction with Valethamate compared to the Active phase delivery internal 
in Control (p = 0.001).
• There was no significant shortening of II stage of labour.
• There was no increase in incidence of instrumental delivery or abdominal 
delivery in either Drotaverine or Valethamate groups.
• The incidence of cervical tears was 2% in both drug groups.
• No case of atonic PPH noted in all 3 groups
• Incidence of  maternal  side  effects  with drotaverine (3%) is  significantly 
less compared to Valethamate (8%).
• There was no significant increase in incidence of meconium stained liquor 
in the drug groups compared to control.
• All newborns in all 3 groups had Apgar score > 7 at 5 minutes. There was 
no intrapartum or early neonatal deaths in all the study groups.
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CONCLUSION
Drotaverine  hydrochloride  is  a  superior  cervical  dilatation  agent 
significantly reducing the duration of labour without any ill effects on the mother 
or  the  fetus.  It  is  significantly  better  than Valethamate  bromide  with less  side 
effects  due  to  selective  action.  Hence  it  is  recommended  that  Drotaverine 
Hydrochloride may be given to low risk women in active labour.
The promising beneficial effects of Drotaverine hydrochloride are available 
in  obstetric  practice  and  in  this  study,  it  has  definitely  proven  to  shorten  the 
duration of labour and provide early relief from distress for the labouring woman. 
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PROFORMA
Name : Age : Occupation :
Address: Socioeconomic Class:
Gravida Para Live Abortion :
LMP : EDD : Booked / Unbooked
Immunisation : Yes / No
H/o. Months amenorrhoea
Complaints : Pain since
Discharge Per vaginum
H/o. Present Pregnancy : I Trimester
II Trimester
III Trimester
Pain started at : Once in :
Duration and frequency increasing : Yes / No
Discharge per vaginum : Yes / No
Colourless / Meconium Stained / Blood Stained
H/o. Bowel or Bladder Disturbance :
Menstrual History :
Menarche:  Cycles: Pain : Yes / No
LMP : EDP :
Obstetric History :
Married Since : Consanguinity - Io
     IIo
I Pregnancy - Baby details :   IIIo
II Pregnancy – 
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Past History :
Known Diabetic : Yes / No Hypertensive : Yes / No
Tuberculosis  : Yes / no Rheumatic fever : Yes / No
Personal History :
Diet : Vegetarian / Non Vegetarian / Mixed Appetite : Good/Moderate
Addiction : Smoking / Drugs Sleep : Good / Moderate
Family History :
Mother : Alive / Dead Father : Alive / Dead Siblings :
H/o. Diabetes : Yes / No Hypertension : Yes / No Tuberculosis : Yes / No
Twins : Yes / No
General Examination :
Built : Thin / Moderate / Obese Height : Weight :
Pallov : Yes / No Jaundice : Yes / No    Pedal edema : Yes / No
BP :   mm of Hg PR :    /mt.    Breast :         Thyroid :
CVS : RVS :    Gait :
Abdominal Examination :
Inspection : 
Longitudinally enlarged: Yes / No   Term : Yes / No
Skin : Normal / Abnormal    Strial : Yes / No Linea Nigra: Yes/No
Fetal Movements : Seen / not seen
Palpation :
Height of uterus : SFH :    cm     Abdominal girth :   cm
Acting : Yes / No EFW :    kg
Fundal Grip : Breech : Yes/ No Head : Yes/No
Umbilical Grip : Back : Left / Right Limbs : Left / Right
Liquor : Adequate / Diminished
I pelvic grip : head engaged/unengaged
II pelvic grip : Head flexed / deflexed. LOA/ROP/ROA/LOP
Auscultation :
Fetal Heart Rate : / minute Tone :
Vaginal Examination :
Cerix : Position : Posterior / Mid Position / Anterior
Consistency : Firm / Medium / Soft
Dilatation :
Effacement :
Station : Bishop’s score
Membranes :
Pelvis :
Drug Used : Dose :
Time of Administration of Drug, Cervical dilatation at time of injection
I dose –
II dose – 
III dose –
Membranes ruptured at :
Colour of Liquor : Clear / Thin  Meconium / Thick Meconium
Whether augmented with oxytocin : Yes / No
Time from Injection (I dose) to full cervical dilatation 
Rate of cervical dilatation :      cm/hr  
II Stage :
Duration
Mode of Delivery : Normal vaginal / Forceps / Ventouse / LSCS
Indication :
Drug Delivery Interval :
Fetal Outcome :
Baby details :
Apgar : 1mt: 5 mt:
Any resuscitation required :
Admission in NICU: Yes / No
III Stage complications :
Cervical Tears : Yes / No
Atomic post partum hemorrhage : Yes / No
Maternal side effects :
Tachycardia : Yes / No Vomiting : Yes / No 
Dryness of mouth : Yes / No
Total number of injections of drugs required : 1 / 2 / 3

